ClinicalTrials.gg
RecruitingNCT07781605Updated Nov 10, 2026

Ambient Temperature and Thermoregulation During Exercise in Children and Youth

An interventional study of Exercise at 22°C and Exercise at 26°C in Body Temperature Changes, Heat Stress and Child Development, sponsored by University of Ottawa. Recruiting at 1 site in Canada. Open to participants aged 9 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of Ottawa · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
9 Years to 25 Years
Sex
All
01

Study summary

Little is known about how children and youth regulate body temperature during exercise across different environmental temperatures compared with young adults, including whether differences in whole-body heat exchange contribute to their responses. The goal of this clinical trial is to determine how ambient temperature affects thermoregulation during exercise in boys and girls aged 9-16 years compared with young adult men and women aged 20-25 years. Participants will complete four study visits at ambient temperatures of 22°C (Celsius; 72°F, Fahrenheit), 26°C (79°F), 31°C (88°F), and 36°C (97°F), while exercising at the same moderate-intensity metabolic heat production of 160 W/m² (W = watts, m = meters). During each visit, participants will complete four 15-minute periods of exercise (exercise bouts 1, 2, 3 and 4 respectively) separated by 15-minute rest periods. Testing will be performed in a whole-body air calorimeter, a specialized chamber that precisely measures heat lost through evaporation and dry heat exchange and the amount of heat stored in the body. These measurements, together with core temperature and heart rate, will allow researchers to determine how increasing ambient temperature affects the body's ability to lose heat and whether these responses differ between children and youth and young adults.

02

Conditions studied

  • Body Temperature Changes
  • Heat Stress
  • Child Development
  • Heat
  • Physiological Stress

Keywords

  • Thermoregulation
  • Heat loss
  • Heat tolerance
  • Heat strain
  • Physical activity
03

In context

Body Temperature Changes

97 studies on the registry are indexed under Body Temperature Changes; 20 are open to participants now.

This study's planned enrollment of 12 is below the median of 40 across 68 interventional studies indexed under Body Temperature Changes.

Browse Body Temperature Changes studies →

Lead sponsor

University of Ottawa is the lead sponsor of 125 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female.
  • Aged 9-16 years or 20-25 years.
  • Habitually active, defined as participating in regular physical activity at least 3 times per week for at least 20 minutes per session over the previous 6 months.
  • Able to understand and communicate in English or French.
  • For participants younger than 18 years, written parental or guardian consent and participant assent are required.

Exclusion criteria

Exclusion Criteria:

  • Acute illness at the time of testing (e.g., cold, flu, or infection).
  • History of a chronic medical condition that may affect thermoregulation, cardiovascular function, or exercise capacity (e.g., cardiovascular disease, metabolic disorders, respiratory disease including asthma requiring regular medication, or neurological disorders).
  • Use of medications known to affect thermoregulation, hydration status, or cardiovascular responses.
  • History of heat-related illness (e.g., heat exhaustion or heat stroke).
  • Digestive abnormalities or gastrointestinal conditions that may contraindicate ingestion of a telemetry pill.
  • Any condition that, in the opinion of the investigators, would compromise participant safety or the integrity of the data.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Exercise at 22°C

    Participants will complete intermittent moderate-intensity exercise at an ambient temperature of 22°C (celsius; 72°F, fahrenheit). Exercise will be performed at a metabolic heat production of 160 W/m² (W = watts, m = meters) and will consist of four 15-minute exercise periods separated by 15-minute rest periods. Exercise workload will be individually adjusted to achieve the prescribed metabolic heat production.

    Other: Exercise at 22°C

  • Experimental
    Exercise at 26°C

    Participants will complete intermittent moderate-intensity exercise at an ambient temperature of 26°C (79°F). Exercise will be performed at a metabolic heat production of 160 W/m² and will consist of four 15-minute exercise periods separated by 15-minute rest periods. Exercise workload will be individually adjusted to achieve the prescribed metabolic heat production.

    Other: Exercise at 26°C

  • Experimental
    Exercise at 31°C

    Participants will complete intermittent moderate-intensity exercise at an ambient temperature of 31°C (88°F). Exercise will be performed at a metabolic heat production of 160 W/m² and will consist of four 15-minute exercise periods separated by 15-minute rest periods. Exercise workload will be individually adjusted to achieve the prescribed metabolic heat production.

    Other: Exercise at 31°C

  • Experimental
    Exercise at 36°C

    Participants will complete intermittent moderate-intensity exercise at an ambient temperature of 36°C (97°F). Exercise will be performed at a metabolic heat production of 160 W/m² and will consist of four 15-minute exercise periods separated by 15-minute rest periods. Exercise workload will be individually adjusted to achieve the prescribed metabolic heat production.

    Other: Exercise at 36°C

Interventions

  • OtherExercise at 22°C

    Participants complete intermittent exercise at a metabolic heat production of 160 W/m² in an ambient temperature of 22°C (72°F).

  • OtherExercise at 26°C

    Participants complete intermittent exercise at a metabolic heat production of 160 W/m² in an ambient temperature of 26°C (79°F).

  • OtherExercise at 31°C

    Participants complete intermittent exercise at a metabolic heat production of 160 W/m² in an ambient temperature of 31°C (88°F).

  • OtherExercise at 36°C

    Participants complete intermittent exercise at a metabolic heat production of 160 W/m² in an ambient temperature of 36°C (97°F).

06

What researchers measure

Primary outcomes

  1. Core temperature

    Core temperature indexed by visceral (telemetry pill) temperature

    Time frame: End of each of the four 15 minutes exercise bouts (average of last 5 minutes)

Secondary outcomes

  1. Evaporative heat loss

    Evaporative heat loss as assessed using a direct air calorimeter

    Time frame: End of each of the four 15 minutes exercise bouts (average of last 5 minutes)

  2. Dry heat loss

    Dry heat loss as assessed using a direct air calorimeter

    Time frame: End of each of the four 15 minutes exercise bouts (average of last 5 minutes)

  3. Whole-body total heat loss

    Total heat loss (evaporative + dry) as assessed using a direct air calorimeter

    Time frame: End of each of the four 15 minutes exercise bouts (average of last 5 minutes)

  4. Body heat storage

    Heat stored in the body for each of the exercise bouts

    Time frame: Change from start to end of exercise for each of the four 15 minutes exercise bouts

  5. Skin temperature

    Skin temperature measured at 8-sites (forehead, chest, scapula, upper arm, forearm, hand, thigh, calf) with mean value calculated as weighted values of 8 sites - forehead 7%, chest 17.5%, scapula 17.5%, upper arm 7%, forearm 7%, hand 5%, thigh 19%, and calf 20%.

    Time frame: End of each of the four 15 minutes exercise bouts (average of last 5 minutes)

  6. Change in skin temperature

    Skin temperature measured at 8-sites (forehead, chest, scapula, upper arm, forearm, hand, thigh, calf) with mean value calculated as weighted values of 8 sites - forehead 7%, chest 17.5%, scapula 17.5%, upper arm 7%, forearm 7%, hand 5%, thigh 19%, and calf 20%.

    Time frame: End of each of the four 15 minutes exercise bouts (average of last 5 minutes)

  7. Heart rate

    Heart rate measured continuously with chest-band telemetric device

    Time frame: End of each of the four 15 minutes exercise bouts (average of last 5 minutes)

  8. Thermal sensation

    Thermal sensation will be assessed using the American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE) 7-point scale ("0=neutral to 7=extremely hot")

    Time frame: End of each of the four 15 minutes exercise bouts (average of last 5 minutes)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2027, 9 months after the start.

Of 44 non-industry interventional studies with no phase under Body Temperature Changes, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 9 months is above that.

Counting every sponsor, half of 44 studies reached it within 5 months; a quarter within 3 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 24, 2026
StartActual
Jul 19, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07781605
Responsible party
Glen P. Kenny (Full Professor, University of Ottawa) — Principal investigator
First posted
Aug 24, 2026
Start date
Jul 19, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Glen P Kenny, PhD
Contact
gkenny@uottawa.ca
6135625800 ext. 4282

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion